Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Evidence dashboardStudies since 2007Updated Jul 31, 2026
ExenatideClinical Trials.
A source-linked view of every Exenatide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 75
- Recruiting
- 11
- Completed
- 37
- Terminated
- 5
- Results posted
- 19
- Average enrollment
- 119
- Countries
- 21
- Highest phase
- Phase 4
Largest indexed study
23,280,000 participants · NCT07188545 →Developer / research origin
AstraZeneca
Evidence summary
Activity is not efficacy.
Exenatide appears in 75 indexed studies: 11 recruiting, 37 completed and 19 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Exenatide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Chinese University of Hong Kong · Cerebral Small Vessel Disease
Phase 2
Recruiting
110
2026-06
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Maisa N. Feghali, MD · Gestational Diabetes
Phase 4
Recruiting
13
2026-04
Showing 6 of 19 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Exenatide for Smoking Cessation and Prevention of Weight Gain
The University of Texas Health Science Center, Houston · Smoking Cessation · Weight Gain
Phase 2
Completed
140
2026-03
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Baylor Research Institute · Type 2 Diabetes Mellitus · Chronic Kidney Disease
Phase 3
Completed
57
2026-02
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Hypopituitarism · Central Diabetes Insipidus
Phase 4
Completed
42
2026-01
Showing 6 of 37 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Exenatide For Reducing the Reinforcing Effects of Cocaine
Christopher D. Verrico · Cocaine Use Disorder
Phase 1
Withdrawn
0
2026-03
Diabetes Islet Preservation Immune Treatment
Camillo Ricordi and Jay Skyler · Diabetes Mellitus, Type 1 · Hypoglycemia
Phase 1 / Phase 2
Withdrawn
0
2026-01
Pharmacogenomics of GLP1 Receptor Agonists
University of Maryland, Baltimore · Type 2 Diabetes
Phase 1
Terminated
63
2025-07
A Trial to Determine the Efficacy and Safety of Presendin in IIH
Invex Therapeutics Ltd. · Idiopathic Intracranial Hypertension
Phase 3
Terminated
14
2024-04
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
University at Buffalo · Type2 Diabetes · Kidney Diseases
Phase 4
Terminated
15
2024-04
Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin
Radboud University Medical Center · Diabetes Mellitus
Not applicable
Terminated
12
2023-07
Showing 6 of 7 studies
Full study index
Search Exenatide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
75 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 39043396 ↗Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024 Jul 23;386:q1645. doi: 10.1136/bmj.q1645. No abstract available.Linked from NCT07702461PMID 33239350 ↗Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, Carty C, Chaput JP, Chastin S, Chou R, Dempsey PC, DiPietro L, Ekelund U, Firth J, Friedenreich CM, Garcia L, Gichu M, Jago R, Katzmarzyk PT, Lambert E, Leitzmann M, Milton K, Ortega FB, Ranasinghe C, Stamatakis E, Tiedemann A, Troiano RP, van der Ploeg HP, Wari V, Willumsen JF. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020 Dec;54(24):1451-1462. doi: 10.1136/bjsports-2020-102955.Linked from NCT07702461PMID 41843416 ↗Currier BS, D'Souza AC, Singh MAF, Lowisz CV, Rawson ES, Schoenfeld BJ, Smith-Ryan AE, Steen JP, Thomas GA, Triplett NT, Washington TA, Werner TJ, Phillips SM. American College of Sports Medicine Position Stand. Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews. Med Sci Sports Exerc. 2026 Apr 1;58(4):851-872. doi: 10.1249/MSS.0000000000003897. Epub 2026 Mar 5.Linked from NCT07702461PMID 36841762 ↗Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023 Feb 25;22(1):41. doi: 10.1186/s12933-023-01765-z.Linked from NCT07702461PMID 38629387 ↗Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18.Linked from NCT07702461PMID 38937282 ↗Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.Linked from NCT07702461PMID 35237446 ↗Shakespear-Druery J, De Cocker K, Biddle SJH, Bennie J. Muscle-Strengthening Exercise Questionnaire (MSEQ): an assessment of concurrent validity and test-retest reliability. BMJ Open Sport Exerc Med. 2022 Feb 14;8(1):e001225. doi: 10.1136/bmjsem-2021-001225. eCollection 2022.Linked from NCT07702461PMID 38450721 ↗Gatta-Cherifi B, Mohammedi K, Cariou T, Poitou C, Touraine P, Raverot G, Brue T, Chanson P, Illouz F, Grunenwald S, Chabre O, Sonnet E, Cuny T, Bertherat J, Czernichow S, Frison E, Tabarin A. Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol. 2024 Mar 30;190(4):257-265. doi: 10.1093/ejendo/lvae024.Linked from NCT02860923
Related pages
Keep researching Exenatide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.